We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
PACB taps a long-read sequencing market projected to reach $1.53B by 2030.
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, announced a collaboration with DNAstack to launch the world’s first global federated dataset of HiFi whole genome sequencing data. Through the HiFi Solves Global Consortium, the initiative enables researchers to securely analyze harmonized genomic datasets across institutions worldwide without centralizing sensitive patient data, a model designed to accelerate rare disease research while maintaining strict data privacy compliance.
For investors, the partnership highlights PacBio’s push to extend the reach of its high-accuracy HiFi sequencing beyond individual labs into large-scale, international research networks.
More on the Collaboration
Under the collaboration, DNAstack is likely to provide the secure, cloud-enabled federated infrastructure that allows participating institutions to connect their PacBio HiFi whole genome sequencing data within a shared network, without transferring or centralizing protected datasets. Researchers can run queries across harmonized genomic and phenotypic data hosted locally at each institution, enabling cross-border analysis while preserving data sovereignty and complying with regional privacy regulations. This federated architecture reduces regulatory friction and removes one of the biggest barriers to large-scale genomic collaboration: the need to physically move sensitive patient data.
The HiFi Solves Global Consortium has grown to nearly 30 clinical and research institutions across 15 countries, collectively connecting or committing more than 10,000 HiFi whole genome sequences. By increasing cohort size and diversity, the collaboration enhances statistical power for rare disease studies, improves interpretation of complex variants such as structural variations and paralogous gene regions, and streamlines workflows that might otherwise require multiple complementary technologies. As the network scales, it creates a recurring ecosystem opportunity for PacBio’s HiFi platform in clinical research settings, reinforcing long-term adoption potential in rare disease genomics.
Industry Prospects Favoring PACB
Per a report by Grand View Research, the global long-read sequencing market size was estimated at $538.9 million in 2024 and is projected to reach $1.53 billion by 2030, expanding at a CAGR of 20.12% from 2025 to 2030.
The major factors driving market growth include the increasing prevalence of genetic diseases like cancers and chromosomal disorders.
Other Developments by PACB
In January, PACB announced that its HiFi whole-genome sequencing technology has been adopted as a first-line approach in a major research effort to study Sudden Unexplained Death in Childhood. PacBio also announced a new community-developed method, CiFi. It enables chromosome-scale, haplotype-resolved genome assemblies from a single sequencing run, even when sample material is limited.
Peers Update
Illumina, Inc. (ILMN - Free Report) has remained active on the strategic front in early 2026. Illumina recently completed the acquisition of SomaLogic from Standard BioTools for $350 million in upfront cash, with additional earnout potential, expanding Illumina’s presence into proteomics and strengthening its multiomics ecosystem. The transaction enhances Illumina’s ability to integrate genomic and proteomic data, reinforcing its long-term strategy of offering more comprehensive molecular insights across research and clinical markets. Through this move, Illumina continues positioning ILMN as a broader life sciences platform rather than solely a sequencing provider.
In product innovation, Illumina introduced TruPath Genome, a whole genome solution aimed at advancing genetic disease research. The company stated that TruPath Genome delivers high-resolution, highly accurate insights, including improved coverage of hard-to-sequence “dark regions.” By strengthening variant detection and expanding genomic profiling capabilities, Illumina is reinforcing its positioning in clinical and translational research while maintaining its focus on sequencing innovation.
10x Genomics, Inc. (TXG - Free Report) most recently reported its fourth quarter and full year 2025 financials, highlighting performance through a challenging macro environment. For the fourth quarter of 2025, 10x Genomics posted revenues of approximately $166 million, with full-year revenues of $642.8 million and a notable increase in cash reserves to over $523 million. The financials showed improved operating and net loss figures compared with prior-year periods, suggesting tighter cost discipline and deeper execution on strategic priorities.
Beyond results, 10x Genomics is expanding partnerships and research initiatives to deepen adoption of its Chromium and Xenium platforms. 10x Genomics has entered collaborations aimed at building AI-ready datasets and advancing single-cell and spatial biology applications in oncology and translational research.
Thermo Fisher Scientific (TMO - Free Report) continues to strengthen its position in life sciences tools, diagnostics and laboratory services through steady product innovation and portfolio expansion. Thermo Fisher Scientific is advancing sequencing, analytical and workflow solutions that support biopharma and research customers, while its recurring consumables model provides durable revenue visibility. This balanced strategy keeps TMO well positioned to capitalize on long-term growth in genomics and drug development markets.
Recently, Thermo Fisher Scientific announced a strategic collaboration with NVIDIA to power AI-based solutions and laboratory automation at scale. The effort will leverage the NVIDIA Artificial Intelligence platform alongside TMO’s solutions to progressively increase the automation, accuracy and speed of laboratories.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub
Key Takeaways
Pacific Biosciences of California, Inc. (PACB - Free Report) , popularly known as PacBio, announced a collaboration with DNAstack to launch the world’s first global federated dataset of HiFi whole genome sequencing data. Through the HiFi Solves Global Consortium, the initiative enables researchers to securely analyze harmonized genomic datasets across institutions worldwide without centralizing sensitive patient data, a model designed to accelerate rare disease research while maintaining strict data privacy compliance.
For investors, the partnership highlights PacBio’s push to extend the reach of its high-accuracy HiFi sequencing beyond individual labs into large-scale, international research networks.
More on the Collaboration
Under the collaboration, DNAstack is likely to provide the secure, cloud-enabled federated infrastructure that allows participating institutions to connect their PacBio HiFi whole genome sequencing data within a shared network, without transferring or centralizing protected datasets. Researchers can run queries across harmonized genomic and phenotypic data hosted locally at each institution, enabling cross-border analysis while preserving data sovereignty and complying with regional privacy regulations. This federated architecture reduces regulatory friction and removes one of the biggest barriers to large-scale genomic collaboration: the need to physically move sensitive patient data.
The HiFi Solves Global Consortium has grown to nearly 30 clinical and research institutions across 15 countries, collectively connecting or committing more than 10,000 HiFi whole genome sequences. By increasing cohort size and diversity, the collaboration enhances statistical power for rare disease studies, improves interpretation of complex variants such as structural variations and paralogous gene regions, and streamlines workflows that might otherwise require multiple complementary technologies. As the network scales, it creates a recurring ecosystem opportunity for PacBio’s HiFi platform in clinical research settings, reinforcing long-term adoption potential in rare disease genomics.
Industry Prospects Favoring PACB
Per a report by Grand View Research, the global long-read sequencing market size was estimated at $538.9 million in 2024 and is projected to reach $1.53 billion by 2030, expanding at a CAGR of 20.12% from 2025 to 2030.
The major factors driving market growth include the increasing prevalence of genetic diseases like cancers and chromosomal disorders.
Other Developments by PACB
In January, PACB announced that its HiFi whole-genome sequencing technology has been adopted as a first-line approach in a major research effort to study Sudden Unexplained Death in Childhood. PacBio also announced a new community-developed method, CiFi. It enables chromosome-scale, haplotype-resolved genome assemblies from a single sequencing run, even when sample material is limited.
Peers Update
Illumina, Inc. (ILMN - Free Report) has remained active on the strategic front in early 2026. Illumina recently completed the acquisition of SomaLogic from Standard BioTools for $350 million in upfront cash, with additional earnout potential, expanding Illumina’s presence into proteomics and strengthening its multiomics ecosystem. The transaction enhances Illumina’s ability to integrate genomic and proteomic data, reinforcing its long-term strategy of offering more comprehensive molecular insights across research and clinical markets. Through this move, Illumina continues positioning ILMN as a broader life sciences platform rather than solely a sequencing provider.
In product innovation, Illumina introduced TruPath Genome, a whole genome solution aimed at advancing genetic disease research. The company stated that TruPath Genome delivers high-resolution, highly accurate insights, including improved coverage of hard-to-sequence “dark regions.” By strengthening variant detection and expanding genomic profiling capabilities, Illumina is reinforcing its positioning in clinical and translational research while maintaining its focus on sequencing innovation.
10x Genomics, Inc. (TXG - Free Report) most recently reported its fourth quarter and full year 2025 financials, highlighting performance through a challenging macro environment. For the fourth quarter of 2025, 10x Genomics posted revenues of approximately $166 million, with full-year revenues of $642.8 million and a notable increase in cash reserves to over $523 million. The financials showed improved operating and net loss figures compared with prior-year periods, suggesting tighter cost discipline and deeper execution on strategic priorities.
Beyond results, 10x Genomics is expanding partnerships and research initiatives to deepen adoption of its Chromium and Xenium platforms. 10x Genomics has entered collaborations aimed at building AI-ready datasets and advancing single-cell and spatial biology applications in oncology and translational research.
Thermo Fisher Scientific (TMO - Free Report) continues to strengthen its position in life sciences tools, diagnostics and laboratory services through steady product innovation and portfolio expansion. Thermo Fisher Scientific is advancing sequencing, analytical and workflow solutions that support biopharma and research customers, while its recurring consumables model provides durable revenue visibility. This balanced strategy keeps TMO well positioned to capitalize on long-term growth in genomics and drug development markets.
Recently, Thermo Fisher Scientific announced a strategic collaboration with NVIDIA to power AI-based solutions and laboratory automation at scale. The effort will leverage the NVIDIA Artificial Intelligence platform alongside TMO’s solutions to progressively increase the automation, accuracy and speed of laboratories.